Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma

Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma

Abstract Background Renal cell carcinoma (RCC) is a highly vascular tumor and patients with low risk metastatic RCC of clear-cell histological sub-type (mccRCC) are treated with tyrosine-kinase inhibitors (TKIs), sunitinib, as the first-line of treatment. Unfortunately, TKI resistance eventually dev...

Full description

Bibliographic Details
Main Authors: Ninadh M. D’Costa, Matthew R. Lowerison, Peter A. Raven, Zheng Tan, Morgan E. Roberts, Raunak Shrestha, Matthew W. Urban, Cesar U. Monjaras-Avila, Htoo Zarni Oo, Antonio Hurtado-Coll, Claudia Chavez-Munoz, Alan I. So
Format: Article
Language:English
Published: BMC 2020-02-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Renal cell carcinoma
Angiogenesis
Metastasis
Sunitinib
Resistance
Tyrosine kinase inhibitors (TKI)
Online Access:https://doi.org/10.1186/s13046-020-1527-y

Internet

https://doi.org/10.1186/s13046-020-1527-y

Similar Items